104807-46-7
Chemical Structure
Methoctramine tetrahydrochloride
- CAS No.: 104807-46-7
- Formula:C36H66Cl4N4O2
- Molecular Weight:728.75
IUPAC Name: N1,N1'-(octane-1,8-diyl)bis(N6-(2-methoxybenzyl)hexane-1,6-diamine) tetrahydrochloride
InChIKey: CDKGGOUDHGSFAF-UHFFFAOYSA-N
SMILES: COC1=C(C=CC=C1)CNCCCCCCNCCCCCCCCNCCCCCCNCC2=C(C=CC=C2)OC.Cl.Cl.Cl.Cl
Biological Activity: Methoctramine tetrahydrochloride is a M2 subtype-preferring muscarinic acetylcholine receptor (mAChR) antagonist. Methoctramine tetrahydrochloride blocks presynaptic inhibitory M2 autoreceptors, relieves negative feedback inhibition, enhances acetylcholine release, and strengthens neuromuscular transmission. Methoctramine tetrahydrochloride is used in research on amyotrophic lateral sclerosis, breast cancer, central cholinergic hypertension, and psychostimulant use disorder[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Methoctramine tetrahydrochloride | 97.0% | Methoctramine tetrahydrochloride is a M2 subtype-preferring muscarinic acetylcholine receptor (mAChR) antagonist. Methoctramine tetrahydrochloride blocks presynaptic inhibitory M2 autoreceptors, relieves negative feedback inhibition, enhances acetylcholine release, and strengthens neuromuscular transmission. Methoctramine tetrahydrochloride is used in research on amyotrophic lateral sclerosis, breast cancer, central cholinergic hypertension, and psychostimulant use disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.97
HY-116294Methoctramine -
Similarity Score 0.60
HY-149515MAO-IN-3 -
Similarity Score 0.57
HY-183624Trimer44NMe -
Similarity Score 0.55
HY-W275220PEA-NBOMe hydrochloride -
Similarity Score 0.55
HY-U00008CP-28888 -
Similarity Score 0.54
HY-13035125H-NBOMe hydrochloride -
Similarity Score 0.54
HY-U00205Dopexamine hydrochloride -
Similarity Score 0.53
HY-106562Dopexamine -
Similarity Score 0.52
HY-W70803325E-NBOMe hydrochloride -
Explore the MedChemAI to find more analogs
References
- [1]. de la Torre E, et al. Muscarinic receptors participation in angiogenic response induced by macrophages from mammary adenocarcinoma-bearing mice. Breast Cancer Research. 2005 Mar 4;7(3):R345. [Content Brief]
- [2]. Dobryakova YV, et al. Administration of muscarinic antagonists induce changes in passive avoidance learning and in synaptic transmission in the CA1 area of the hippocampus. Acta neurobiologiae experimentalis. 2018;78(2):132-139.
- [3]. Ozkutlu U, et al. Central muscarinic M2 cholinoceptors involved in cholinergic hypertension. European journal of pharmacology. 1993 Dec 21;250(3):349-54.
- [4]. Xu ZP, et al. Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response. International immunopharmacology. 2012 Nov;14(3):320-7.
- [5]. Jakubík J, et al. Molecular mechanisms of methoctramine binding and selectivity at muscarinic acetylcholine receptors. Molecular pharmacology. 2014 Aug 1;86(2):180-92.
- [6]. Joseph L, et al. Effects of muscarinic receptor antagonists on cocaine discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor knockout mice. Behav Brain Res. 2017 Jun 30;329:75-83.
